Cargando…

Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study

BACKGROUND: It has been shown that peroxisome proliferator-activated receptors (PPAR) have physiological and pharmacological ligands. The objective is to assess the association between thiazolidinediones (TZDs) and the occurrence of gastric cancer. METHODS: We conducted a population-based nested cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Shen-Shong, Hu, Hsiao-Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850900/ https://www.ncbi.nlm.nih.gov/pubmed/24041200 http://dx.doi.org/10.1186/1471-2407-13-420

Ejemplares similares

Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus
por: Zhao, Houyu, et al.
Publicado: (2022)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones
por: Alemán-González-Duhart, D., et al.
Publicado: (2016)

Type 2 Diabetes: Uses of thiazolidinediones and insulin
por: T. Bloomgarden, Zachary
Publicado: (2011)

Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis
por: Liu, Yang, et al.
Publicado: (2018)

Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes: A nationwide, population-based, case-control study
por: Chen, Shih-Wei, et al.
Publicado: (2013)

Redefining the role of thiazolidinediones in the management of type 2 diabetes
por: Barnett, Anthony H
Publicado: (2009)

Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: A retrospective cohort study
por: Zhao, Houyu, et al.
Publicado: (2023)

Thiazolidinediones: the Forgotten Diabetes Medications
por: Lebovitz, Harold E.
Publicado: (2019)

Thiazolidinediones: An In–Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus
por: Long, Nathan, et al.
Publicado: (2021)

Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
por: Tseng, Chin-Hsiao
Publicado: (2023)

Association of hepatocellular carcinoma with thiazolidinediones use: A population-based case-control study
por: Lai, Shih-Wei, et al.
Publicado: (2020)

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022)

Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
por: Yen, Fu-Shun, et al.
Publicado: (2023)

Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: a meta-analysis
por: Xu, Chunmei, et al.
Publicado: (2018)

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
por: Stafford, John M, et al.
Publicado: (2007)

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

Long-Term Use of Steroids Protects from the Development of Symptomatic Diverticulitis Requiring Hospitalization in the Asian Population
por: Chang, Shen-Shong, et al.
Publicado: (2015)

Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case–control study
por: Chen, Kuan-Yuan, et al.
Publicado: (2021)

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
por: Lim, Soo, et al.
Publicado: (2017)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Thiazolidinedione derivatives as novel GPR120 agonists for the treatment of type 2 diabetes
por: Wang, Xuekun, et al.
Publicado: (2022)

Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015)

Thiazolidinediones and bone fractures
por: Kaku, Kohei, et al.
Publicado: (2011)

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
por: Horita, Shoko, et al.
Publicado: (2015)

Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
por: Lee, Seung Eun, et al.
Publicado: (2022)

Beneficial Effects of Thiazolidinediones on Diabetic Nephropathy in OLETF Rats
por: Lee, Mi Young, et al.
Publicado: (2007)

The effect of metformin and thiazolidinedione use on lung cancer in diabetics
por: Mazzone, Peter J, et al.
Publicado: (2012)

Response to: Critical commentary on the association between thiazolidinedione use and dementia risk in patients with type 2 diabetes
por: Zhao, Houyu, et al.
Publicado: (2023)

Potential Therapeutic Effects of Thiazolidinedione on Malignant Glioma
por: Sheu, Meei-Ling, et al.
Publicado: (2022)

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes
por: Wen, Yu-Wen, et al.
Publicado: (2011)

Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study
por: Carney, Greg A, et al.
Publicado: (2012)

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications
por: Behzad, Molavi, et al.
Publicado: (2007)

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
por: Yen, Fu‐Shun, et al.
Publicado: (2020)

Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2023)

Effects of Thiazolidinedione Therapy on Inflammatory Markers of Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Chen, Rui, et al.
Publicado: (2015)

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
por: Kim, Sun Woo
Publicado: (2010)

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
por: Chen, Hsin-Hung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_da4lo3flhrqvvgocn9dcd1kflh